Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL249319 | 0.97 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL50775 | 0.97 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL14343482 | 0.97 | SLC22A6 (0.39) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL5195845 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL4823149 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL11696724 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL7632260 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL5160188 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL11586415 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 | |
| Aspartic Acid SCHEMBL896679 | 0.95 | SLC22A6 (0.38) | SLC22A6GABRR1LMNATDP1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119679821-A | Medicament for preventing atrial fibrillation after coronary artery bypass grafting operation, and use method and application thereof | 中国医学科学院阜外医院 | 2025-03-25 | — | — | CN | claimed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | claimed |
| CN-118751186-B | Magnesium potassium aspartate synthesis equipment and process for improving energy metabolism | 湖南德邦生物科技股份有限公司 | 2024-11-19 | — | — | CN | claimed |
| CN-118751186-A | Magnesium potassium aspartate synthesis equipment and process for improving energy metabolism | 湖南德邦生物科技股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-12071710-B2 | Antibody library and antibody screening method using same | MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH (KR) | 2024-08-27 | — | — | US | claimed |
| CN-118477116-A | Chinese medicinal nutrient composition for improving insulin function and preventing complications | 柯宏 | 2024-08-13 | — | — | CN | claimed |
| CN-118319851-A | Sodium fructose diphosphate oral solution for assisting myocardial infarction treatment and preparation method thereof | 江苏锦瑞制药有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-110740725-B | Composition containing benzoic acid amide compound and cyclodextrin solubilizer | 株式会社爱茉莉太平洋 | 2024-01-12 | — | — | CN | claimed |
| CN-117357634-A | Protein injection and preparation method thereof | 郑州原子高科医药有限公司 | 2024-01-09 | — | — | CN | claimed |
| EP-3610865-B1 | COMPOSITION COMPRISING BENZOIC ACID AMIDE COMPOUND AND CYCLODEXTRIN SOLUBILIZING AGENT | AMOREPACIFIC CORP (KR) | 2023-07-12 | — | — | EP | claimed |
| CN-1404862-A | Compound blood-pressure reducing medicine | QU JINGMING (CN) | 2003-03-26 | — | — | CN | claimed |
| EP-1198237-A1 | HERBAL COMPOSITIONS FOR ITCHY OR INFECTED SKIN | Shah, Eladevi (GB) | 2002-04-24 | — | — | EP | claimed |
| US-6296859-B1 | IN COSMETICS | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2001-10-02 | — | — | US | claimed |
| US-20010002257-A1 | Composition comprising a lipoamino acid and the constituents of a tannin-rich plant extract, and cosmetic use thereof | STOLZ CORINNE (FR) | 2001-05-31 | — | — | US | claimed |
| WO-2001017539-A1 | HERBAL COMPOSITIONS FOR ITCHY OR INFECTED SKIN | SHAH ELADEVI (GB) | 2001-03-15 | — | — | WO | claimed |
| EP-0904374-A1 | PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PROCESS FOR PREPARING THE SAME AND THEIR USE | Bundesrepublik Deutschland vertreten durch den Bundesminister für Gesundheit (DE) | 1999-03-31 | — | — | EP | claimed |
| WO-1997041231-A1 | PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PROCESS FOR PREPARING THE SAME AND THEIR USE | BUNDESREPUBLIK DEUTSCHLAND vertreten durch DEN BUNDESMINISTER FÜR GESUNDHEIT (DE) | 1997-11-06 | — | — | WO | claimed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | claimed |
| EP-0230869-A2 | Construction of an IgG binding protein to facilitate downstream processing using protein engineering | Kabi Pharmacia AB (SE) | 1987-08-05 | — | — | EP | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002257-A1 | Composition comprising a lipoamino acid and the constituents of a tannin-rich plant extract, and cosmetic use thereof | LIPC, PLIN1, LRAT | SLC22A6 1870/4885GABRR1 2851/4885LMNA 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.